CJC-1295 / Ipamorelin
For laboratory research use only — not for human or animal consumption.
Research-grade CJC-1295 (no DAC) / Ipamorelin blend, pairing a GHRH(1-29) analog with a selective ghrelin-receptor agonist, ≥99% HPLC purity with third-party batch-level Certificate of Analysis. For laboratory research use only.
Description
CJC-1295 w/o DAC 5MG / Ipamorelin 5MG
CJC-1295 w/o DAC / Ipamorelin is a research blend pairing a GHRH analog with a selective GHRP. Preclinical studies investigate their synergistic stimulation of the growth hormone axis in laboratory models.
Key Research Areas
- • CJC-1295 studied for GHRH-mediated GH and IGF-1 elevation in research models.
- • Ipamorelin investigated for selective ghrelin receptor agonism and pulsatile GH release.
- • Blend examined for complementary pathways enhancing GH secretion profiles in laboratory settings.
Product Specifications
| Product | CJC-1295 w/o DAC / Ipamorelin Blend |
| CAS Number | CJC-1295: 863288-34-0; Ipamorelin: 170851-70-4 |
| Molecular Formula | CJC-1295: C152H252N44O42; Ipamorelin: C38H49N9O5 |
| Molar Mass | CJC-1295: ~3367.9 g/mol; Ipamorelin: 711.85 g/mol |
| Sequence | CJC-1295: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2; Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Synonyms | CJC-1295 no DAC / Ipamorelin Blend |
| Purity | ≥99% (HPLC) |
| Form | Lyophilized powder |
| Storage | −20°C (−4°F) long-term; 2–8°C (36–46°F) reconstituted |
| Solubility | Bacteriostatic water for laboratory use |
Mechanism of Action
The two peptides act on complementary receptors of the growth-hormone axis. CJC-1295 without DAC (modified GRF 1–29) is a tetra-substituted GHRH(1–29) analog that binds the GHRH receptor on pituitary somatotrophs and raises cAMP; the amino-acid substitutions increase resistance to DPP-IV cleavage relative to native GHRH. Ipamorelin is a pentapeptide agonist of the growth hormone secretagogue receptor 1a (ghrelin receptor) that stimulates GH release with reported selectivity over ACTH and cortisol responses in animal studies. Co-administration in preclinical models has been reported to produce additive pulsatile GH release. Observations summarized here derive from in vitro assays and animal models; the material sold on this page has not been evaluated in controlled human trials.
Research Literature
- • Jetté et al. (2005) — hGRF(1-29) analogs activating the GRF receptor on the anterior pituitary in rats; identification of CJC-1295. PMID: 15817669.
- • Alba et al. (2006) — CJC-1295 in the GHRH knockout mouse. PMID: 16822960.
- • Venkova et al. (2009) — ipamorelin, a ghrelin mimetic, in a rodent model of postoperative ileus. PMID: 19289567.
- • Additional peer-reviewed literature is indexed on PubMed under the compound name.
Reconstitution & Storage
Lyophilized CJC-1295 / Ipamorelin is stable at −20°C or colder in its sealed vial; −80°C is preferable for long-term archival. Reconstitute in bacteriostatic water (0.9% benzyl alcohol) to a laboratory working concentration of 1–5 mg/mL for in vitro use. Once reconstituted, refrigerate at 2–8°C and use within approximately 30 days. Aliquot into single-use vials at reconstitution to avoid repeated freeze-thaw cycles of the working solution. Every batch ships with a third-party Certificate of Analysis; request the analytical file for your batch at /coa.
Research Use Only
For research use only. Not intended for human or veterinary consumption, therapeutic use, dietary supplementation, cosmetic use, or clinical application. Not FDA-approved. Purchasers confirm the material will be used solely for in vitro laboratory research and not administered to humans or animals.
